Several predictive and prognostic markers, such as age, menopausal status, tumor grade, the value of Ki-67 proliferative index, presence of tumor-infiltrating lymphocytes (TILs), BRCA1/2 status, and programmed death-ligand 1 (PDL1) expression, could be used in clinical practice [22,23]. This evidence concerns the gene BRCA1 and neoplasm.